UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2024		24,875,587
Beginning balance at Dec. 31, 2024	$ (33,415)	$ 2	$ 752,649	$ (786,066)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)		108,072
Issuance of common stock	139		139
Stock-based compensation costs	529		529
Voluntary surrender of shares by shareholder (in shares)		(301)
Net loss	(11,759)			(11,759)
Ending balance (in shares) at Mar. 31, 2025		24,983,358
Ending balance at Mar. 31, 2025	(44,506)	$ 2	753,317	(797,825)
Beginning balance (in shares) at Dec. 31, 2024		24,875,587
Beginning balance at Dec. 31, 2024	(33,415)	$ 2	752,649	(786,066)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(32,872)
Ending balance (in shares) at Sep. 30, 2025		54,583,513
Ending balance at Sep. 30, 2025	47,485	$ 5	866,418	(818,938)
Beginning balance (in shares) at Mar. 31, 2025		24,983,358
Beginning balance at Mar. 31, 2025	(44,506)	$ 2	753,317	(797,825)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)		12,500,000
Issuance of common stock	40,349	$ 1	40,348
Stock-based compensation costs	635		635
Vesting of restricted stock units (in shares)		355,121
Net loss	(11,737)			(11,737)
Ending balance (in shares) at Jun. 30, 2025		37,838,479
Ending balance at Jun. 30, 2025	(15,259)	$ 3	794,300	(809,562)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)		16,212,409
Issuance of common stock	69,515	$ 2	69,513
Exercise of warrants (in shares)		532,625
Exercise of warrants	2,237		2,237
Stock-based compensation costs	368		368
Net loss	(9,376)			(9,376)
Ending balance (in shares) at Sep. 30, 2025		54,583,513
Ending balance at Sep. 30, 2025	$ 47,485	$ 5	866,418	(818,938)
Beginning balance (in shares) at Dec. 31, 2025	83,025,384	83,025,384
Beginning balance at Dec. 31, 2025	$ 213,695	$ 8	1,040,417	(826,730)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of warrants (in shares)		8,206,833
Exercise of warrants	43,458	$ 1	43,457
Stock-based compensation costs	19,130		19,130
Taxes withheld related to net share settlement of equity awards	(4,197)		(4,197)
Vesting of restricted stock units (in shares)		128,384
Net loss	(48,287)			(48,287)
Ending balance (in shares) at Mar. 31, 2026		91,360,601
Ending balance at Mar. 31, 2026	$ 223,799	$ 9	1,098,807	(875,017)
Beginning balance (in shares) at Dec. 31, 2025	83,025,384	83,025,384
Beginning balance at Dec. 31, 2025	$ 213,695	$ 8	1,040,417	(826,730)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	$ (95,182)
Ending balance (in shares) at Sep. 30, 2026	93,183,554	93,183,554
Ending balance at Sep. 30, 2026	$ 237,552	$ 9	1,159,455	(921,912)
Beginning balance (in shares) at Mar. 31, 2026		91,360,601
Beginning balance at Mar. 31, 2026	223,799	$ 9	1,098,807	(875,017)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock (in shares)		1,476,538
Issuance of common stock	35,753		35,753
Exercise of warrants (in shares)		1,000
Exercise of warrants	4		4
Stock-based compensation costs	13,036		13,036
Taxes withheld related to net share settlement of equity awards	(985)		(985)
Vesting of restricted stock units (in shares)		292,255
Net loss	(20,750)			(20,750)
Ending balance (in shares) at Jun. 30, 2026		93,130,394
Ending balance at Jun. 30, 2026	250,857	$ 9	1,146,615	(895,767)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of warrants (in shares)		1,873
Exercise of warrants	8		8
Stock-based compensation costs	12,832		12,832
Vesting of restricted stock units (in shares)		51,287
Net loss	$ (26,145)			(26,145)
Ending balance (in shares) at Sep. 30, 2026	93,183,554	93,183,554
Ending balance at Sep. 30, 2026	$ 237,552	$ 9	$ 1,159,455	$ (921,912)